<?xml version="1.0" encoding="iso-8859-1"?>
<?xml-stylesheet type="text/xsl" href="atom.xsl"?>
<feed xmlns="http://www.w3.org/2005/Atom">
       <title>Eli Lilly			
 - livepress.com</title>
      <link>http://eli-lilly.livepress.com</link>
			<id>http://eli-lilly.livepress.com</id>
  <updated>2006-07-27 03:05:38</updated>
  <entry>
    <title><![CDATA[State of Mississippi Files Lawsuit Against Eli Lilly and Company Over Zyprexa]]></title>
    <link href="http://livepress.com/go/?127869"/>
    <id>http://livepress.com/go/?127869</id>
    <updated>2006-07-27 03:02:59</updated>
    <summary><![CDATA[   Mississippi Attorney General Jim Hood has filed a lawsuit against  Eli Lilly  and Company for claims arising from Lilly&#8217;s sale and marketing of its antipsychotic prescription drug, Zyprexa&#38;reg;. The suit was filed in the State Circuit Court of Lafayette County, according to State of Mississippi Special Assistant Attorney General Tim Balducci of the Langston Law Firm in Booneville, Miss. 

                        

      ]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Eli Lilly And Co. 2Q Earnings Skyrocket]]></title>
    <link href="http://livepress.com/go/?124584"/>
    <id>http://livepress.com/go/?124584</id>
    <updated>2006-07-21 16:44:51</updated>
    <summary><![CDATA[Pharmaceutical company  Eli Lilly  and Co. on Friday said its second-quarter earnings rose as the company generated more revenue from newer drugs. Lilly also noted that Cymbalta, its depression treatment drug, witnessed stronger sales in the quarter....]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Lilly reports strong earnings, after year-ago loss 
    (Reuters)
]]></title>
    <link href="http://livepress.com/go/?124262"/>
    <id>http://livepress.com/go/?124262</id>
    <updated>2006-07-21 07:24:31</updated>
    <summary><![CDATA[    Reuters -  Eli Lilly  and Co.  on Friday 
reported strong second-quarter earnings, fueled by strong 
revenue growth of newer drugs, including an almost doubling of 
sales for its Cymbalta depression treatment.  ]]></summary>
  </entry>
  <entry>
    <title><![CDATA[U.S. approves drug for ovarian cancer, spurns panel 
    (Reuters)
]]></title>
    <link href="http://livepress.com/go/?122953"/>
    <id>http://livepress.com/go/?122953</id>
    <updated>2006-07-17 15:32:38</updated>
    <summary><![CDATA[Reuters - The U.S. Food and Drug Administration 
approved the drug Gemzar for treating recurrent ovarian  cancer , 
ignoring the advice given by an FDA panel earlier this year 
that had strongly recommended against approval,  Eli Lilly  and 
Co., the drug maker, said Monday.]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Drug cos. set sights on diabetes care 
    (AP)
]]></title>
    <link href="http://livepress.com/go/?118239"/>
    <id>http://livepress.com/go/?118239</id>
    <updated>2006-07-04 22:47:01</updated>
    <summary><![CDATA[AP - Drug companies are racing to capture the ballooning market in  diabetes  care.  Pfizer  Inc. plans to debut Exubera, its new inhaled insulin treatment, in July, and  Merck  &amp; Co., Novartis AG and  Eli Lilly  and Co. are awaiting FDA approval for new  diabetes  products that could generate hundreds of millions of dollars in sales.]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Drug shown to cut diabetics' vision loss 
    (AP)
]]></title>
    <link href="http://livepress.com/go/?104511"/>
    <id>http://livepress.com/go/?104511</id>
    <updated>2006-06-12 17:04:58</updated>
    <summary><![CDATA[AP - An experimental  Eli Lilly  and Co. drug reduced vision loss in diabetics by inhibiting an enzyme that damages the eye's light-sensing retina, according to the results of two clinical trials.]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Lilly drug helps reduce diabetic vision loss: study 
    (Reuters)
]]></title>
    <link href="http://livepress.com/go/?103991"/>
    <id>http://livepress.com/go/?103991</id>
    <updated>2006-06-11 18:51:44</updated>
    <summary><![CDATA[Reuters - An experimental drug by  Eli Lilly  and 
Co.  showed promise in reducing vision loss caused by 
the effects of  diabetes  on the retina, according to combined 
data from a pair of late-stage clinical trials presented on 
Sunday.]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Barr says Lilly sues to stop generic weekly Prozac 
    (Reuters)
]]></title>
    <link href="http://livepress.com/go/?85269"/>
    <id>http://livepress.com/go/?85269</id>
    <updated>2006-05-11 11:23:04</updated>
    <summary><![CDATA[Reuters - Barr  Pharmaceuticals  Inc.  on 
Thursday said  Eli Lilly  & Co.  has sued the company, 
claiming Barr's generic weekly form of anti-depressant Prozac 
infringes the patent on Lilly's branded medicine.]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Ariad's Shares Climb 40 Percent After It Wins Patent Case]]></title>
    <link href="http://livepress.com/go/?82436"/>
    <id>http://livepress.com/go/?82436</id>
    <updated>2006-05-05 03:04:29</updated>
    <summary><![CDATA[ Ariad  Pharmaceuticals  Inc. shares climbed up to 40 percent on Thursday after the company announced it won a patent infringement case against  Eli Lilly  and Co.
 Reuters reports a federal court in Massachusetts decided that Lilly's osteoporosis...]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Schering-Plough, Merck impress, Lilly disappoints 
    (Reuters)
]]></title>
    <link href="http://livepress.com/go/?72458"/>
    <id>http://livepress.com/go/?72458</id>
    <updated>2006-04-20 16:26:04</updated>
    <summary><![CDATA[Reuters - Stellar sales of their shared 
cholesterol drugs spurred  Schering-Plough  Corp. and  Merck  & Co. 
to better-than-expected quarterly results on Thursday, but 
investors were disappointed by  Eli Lilly  and Co. as sales of 
its biggest product continued to slide.]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Eli Lilly first quarter profit rises 
    (Reuters)
]]></title>
    <link href="http://livepress.com/go/?72110"/>
    <id>http://livepress.com/go/?72110</id>
    <updated>2006-04-20 07:34:40</updated>
    <summary><![CDATA[    Reuters -  Eli Lilly  and Co.  on Thursday 
reported higher first-quarter profit as price increases helped 
offset the impact of declining sales of some of its most 
important drugs.  ]]></summary>
  </entry>
  <entry>
    <title><![CDATA[New Cancer Drug Shows Fewer Side Effects 
    (AP)
]]></title>
    <link href="http://livepress.com/go/?70491"/>
    <id>http://livepress.com/go/?70491</id>
    <updated>2006-04-18 02:10:01</updated>
    <summary><![CDATA[    AP - Women at high risk of breast cancer after menopause often shun a protective drug for fear of side effects. Now a striking study shows a widely used bone drug prevents breast cancer, too &amp;#151; a safer yet equally effective alternative to that old standby tamoxifen.  ]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Evista as good as tamoxifen for breast cancer: study 
    (Reuters)
]]></title>
    <link href="http://livepress.com/go/?70300"/>
    <id>http://livepress.com/go/?70300</id>
    <updated>2006-04-17 20:12:58</updated>
    <summary><![CDATA[    Reuters - The osteoporosis drug Evista works 
as well as tamoxifen in reducing the risk of  breast cancer  in 
high-risk older women, with fewer dangerous side effects, 
researchers said on Monday.  ]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Osteoporosis Drug Cuts Breast Cancer Risk]]></title>
    <link href="http://livepress.com/go/?70239"/>
    <id>http://livepress.com/go/?70239</id>
    <updated>2006-04-17 18:12:37</updated>
    <summary><![CDATA[  Eli Lilly  and Co's Evista osteoporosis drug works as well as the older tamoxifen in reducing the risk of  breast cancer  in high-risk women, with fewer dangerous side effects, researchers said on Monday. 
 The results of the 19,000-woman...]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Lilly bone drug cuts breast cancer risk: study 
    (Reuters)
]]></title>
    <link href="http://livepress.com/go/?70108"/>
    <id>http://livepress.com/go/?70108</id>
    <updated>2006-04-17 14:39:51</updated>
    <summary><![CDATA[    Reuters -  Eli Lilly  and Co&#039;s Evista 
osteoporosis drug works as well as the older tamoxifen in 
reducing the risk of  breast cancer  in high-risk women, with 
fewer dangerous side effects, researchers said on Monday.  ]]></summary>
  </entry>
  <entry>
    <title><![CDATA[Lilly drug cuts breast cancer risk, fewer side-effects 
    (Reuters)
]]></title>
    <link href="http://livepress.com/go/?70104"/>
    <id>http://livepress.com/go/?70104</id>
    <updated>2006-04-17 14:24:54</updated>
    <summary><![CDATA[    Reuters - Evista,  Eli Lilly  and Co&#039;s 
osteoporosis drug, works just as well as the older drug 
tamoxifen in reducing the risk of  breast cancer  in high-risk 
women, and without some of the dangerous side-effects, 
researchers said on Monday.  ]]></summary>
  </entry>
</feed>